Phase I clinical study of a novel lipophilic platinum complex (SM-11355) in patients with hepatocellular carcinoma refractory to cisplatin/lipiodol

SM-11355 is a platinum complex developed to treat hepatocellular carcinoma (HCC). It is administered via the hepatic artery, using a carrier, lipiodol, that consists of ethyl esters of iodized poppy seed oil. We have performed a phase I clinical trial of an SM-11355-lipiodol formulation in 11 HCC pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujiyama, S, Shibata, J, Maeda, S, Tanaka, M, Noumaru, S, Sato, K, Tomita, K
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2003
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394416/
https://www.ncbi.nlm.nih.gov/pubmed/14583758
http://dx.doi.org/10.1038/sj.bjc.6601318

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394416/
https://www.ncbi.nlm.nih.gov/pubmed/14583758
http://dx.doi.org/10.1038/sj.bjc.6601318

Ejemplares similares